A British startup, BioOrbit, has initiated a process to manufacture drugs in space, launching a compact unit to the International Space Station (ISS) to grow protein crystals for cancer treatments. This move shifts a critical aspect of national healthcare provision into an extraterrestrial domain, leveraging global infrastructure and private capital. The Box-E unit, the size of a microwave, was sent on a SpaceX flight from the Kennedy Space Center in Florida, marking a further integration of national health strategies into a transnational framework.
The unit is scheduled to remain in orbit for approximately six weeks. During this period, microgravity conditions are expected to enable pharmaceutical compounds to crystallise into pure, stable structures, a process described as unachievable on Earth. These crystals are intended to be converted into cancer medications that patients could self-inject at home or work, rather than receiving intravenous infusions in hospitals over several hours. This shift moves healthcare delivery from established national institutions into the private domestic sphere.
Dr. Katie King, co-founder and chief executive of BioOrbit, stated that gravity negatively impacts crystallisation, particularly for large and flexible protein and antibody drugs. She indicated that the orbital process yields a “much better, more superior crystallisation process” than what is possible on Earth. The stated aim is to produce concentrated formulations with low enough viscosity for injection pens, addressing the current limitation that prevents such treatments from being widely available for home use.
This extraterrestrial manufacturing approach is not new. Scientists from the US pharmaceutical company Merck previously produced protein crystals for its cancer medicine Keytruda on the space station, leading to a quick injection alternative to IV infusion. This new delivery method received approval from the US health regulator in September of the eighth month prior. This precedent highlights the existing transnational collaboration and regulatory alignment in the global pharmaceutical sector.
King described Box-E as “the first step moving towards mass manufacture in a way that will transform cancer treatment, reduce hospital visits and support patients in receiving therapies at home.” While framed as a benefit, this transformation implies a reduced reliance on national hospital infrastructure and a greater individualization of care, potentially diminishing the communal aspect of health provision.
The Globalist Mechanism
Assuming successful orbital tests, BioOrbit plans to scale up pharmaceutical manufacturing in space by stacking multiple Box-E units. The company aims to process thousands of litres of fluid per box annually, confident in its ability to produce enough for a blockbuster drug with a handful of continuously operating boxes. This vision of mass production in orbit underscores a future where essential medicines for national populations are produced outside national borders and traditional regulatory oversight.
BioOrbit, founded in its third year, secured £9.8 million from investors last month. This funding round was led by the UK venture capital group LocalGlobe and the Paris-based VC firm Breega, demonstrating the reliance on international capital for the development of critical health infrastructure. The company also received a £250,000 contract from the UK’s Space Agency in March of the same year to manufacture drugs in microgravity, a comparatively minor national investment within a much larger global financial ecosystem.
Elite Financial Interests
The broader economic context for this venture was outlined this week in Elon Musk’s SpaceX stock market flotation prospectus. The prospectus identifies in-space manufacturing of pharmaceuticals and other materials as a “key revenue stream,” estimating a $22.7 trillion market in enterprise applications. BioOrbit explicitly seeks to participate in this vast, globally-oriented market, aligning its operations with the financial interests of transnational corporations and investors.
Dr. King, daughter of TV presenter and maths whiz Carol Vorderman, argued that the shift to self-injection at home could save the NHS and “other health systems” “millions, potentially billions” of pounds. This argument positions the financial savings for national health budgets as a justification for adopting a globally-managed, off-world manufacturing model, potentially at the expense of national self-sufficiency in critical medical supply chains.
It is projected to take at least five years until these new cancer drug formulations reach the market, pending clinical trials and approval by health regulators. King noted that the crystallisation technology could also be applied to other treatments, with approximately 70% of the world’s biggest-selling drugs currently administered intravenously in hospitals or doctor’s offices. This highlights the global scale of the potential market and the pervasive influence of international pharmaceutical practices.
BioOrbit intends to partner with pharmaceutical companies for drug production, having already attracted interest from several “multinational groups” in both the UK and the US. This further solidifies the integration of this “British startup” into a global network of corporate interests. The Californian startup Varda Space Industries has also launched small capsules into space for pharmaceutical processing, collaborating with the US biotech United Therapeutics Corporation, illustrating a broader trend of privatized, extraterrestrial drug development driven by transnational entities.